what is semaglutide glp-1 Comparing Ozempic, Wegovy and Other Drugs Ozempic® (semaglutide) and Mounjaro™ (tirzepatide),

Weight Loss Comparison: Injectable Semaglutide (Wegovy 2.4 mg weekly): Average weight loss: 14.9% of body weight Duration: 68 weeks Patients losing 5%+: 86.4% Patients losing 10%+: 69.1% Patients losing 15%+: 50.5% Injectable Tirzepatide (Zepbound 15 mg weekly): Average weight loss: 22.5% of body weight Duration: 72 weeks Patients losing 5%+: 96% Patients losing 10%+: 89% Patients losing 15%+: 78% Patients losing 20%+: 63% Oral Semaglutide (Rybelsus 14 mg daily): Average weight loss: 3-5% of body weight Duration: 26-52 weeks depending on study Patients losing 5%+: Approximately 30-40% Patients losing 10%+: Less than 10% Patients losing 15%+: Rare Real-World Weight Loss Examples: Starting Weight: 250 pounds Starting Weight: 200 pounds Why Such a Big Difference

Enrolled subjects started the study either within the Placebo (PLC, n = 35) or Moringa (MO, n = 38) treatment groups

Sinai Hospital has received grants from Merck, Novo Nordisk, and Takeda for investigator-initiated preclinical studies of glucagon-like peptide action in the Drucker lab

AbbVie Announces Positive Topline Results from a Phase 1 Multiple Ascending Dose Study of ABBV-295, a Long-Acting Amylin Analog, in Adults

Month 2: If you're tolerating the starting dose well, your provider will increase it to the next step, typically 0.5 mg weekly